Biofil Chemicals & Pharmaceuticals
NSE: BIOFILCHEM · ISIN INE829A01014 · Healthcare
₹30.75−0.18 (−0.58%)
Monday 9 November, 11:43 IST. Delayed. Source: Yahoo Finance.
Price chart
This chart is unavailable right now.
The day
- Previous close
- ₹30.93
- Open
- ₹31.60
- Day high
- ₹31.60
- Day low
- ₹30.66
Listed on NSE since 12 June 1996.
Key numbers
- Market value
- ₹50.07 Cr
- P/E (trailing)
- 181.00
- EPS (trailing)
- ₹0.17
- Price to book
- 2.33
- Dividend yield
- 0.00%
- Debt to equity
- 0.14
- Profit margin
- 1.4%
- Beta
- 0.58
- Volume today
- 2,112
- Average volume
- 42,812
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹30.04 Cr | ₹56.04 L |
| FY24 | ₹40.04 Cr | ₹70.92 L |
| FY25 | ₹33.40 Cr | ₹55.77 L |
| FY26 | ₹28.40 Cr | ₹2.79 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | ₹12 Cr | ₹10.91 L | −95.5% |
| Q4 FY26Jan–Mar 2026Audited | ₹8 Cr | ₹21.22 L | +6.3% |
| Q3 FY26Oct–Dec 2025 | ₹85.63 L | ₹7.92 L | – |
| Q2 FY26Jul–Sep 2025 | ₹14 Cr | ₹8.36 L | – |
| Q1 FY26Apr–Jun 2025 | ₹6 Cr | ₹2 Cr | – |
| Q4 FY25Jan–Mar 2025Audited | ₹8 Cr | ₹19.96 L | – |
Source: Biofil Chemicals & Pharmaceuticals’s results filed with NSE, standalone (the company alone). Net profit is the share of Biofil Chemicals & Pharmaceuticals’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | March 2026 | September 2025 |
|---|---|---|
| Fixed assets | ₹7 Cr | ₹7 Cr |
| Inventories | ₹4 Cr | ₹3 Cr |
| Owed by customers | ₹28 Cr | ₹41 Cr |
| Cash and equivalents | ₹6.39 L | ₹23.44 L |
| Total assets | ₹43 Cr | ₹55 Cr |
| Borrowings | ₹3 Cr | ₹2.00 L |
| Total liabilities | ₹21 Cr | ₹34 Cr |
| Shareholders’ equity | ₹22 Cr | ₹21 Cr |
Source: Biofil Chemicals & Pharmaceuticals’s half-yearly statements of assets and liabilities filed with NSE, standalone. Companies file these every September and March.
About Biofil Chemicals & Pharmaceuticals
Biofil Chemicals and Pharmaceuticals Limited engages in the manufacturing and trading of pharmaceutical products in India. It operates through Pharma and Chemical segments. The company offers basic drugs and chemicals, including sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrus fumerate, micro crystalline cellulose, and dicyclomine hydrochloride. It also provides ferrous sulphate in crystal, exsiccated, and granular form; microcrystalline cellulose powder; cellulose powder; calcium carbonate; and sodium chloride. In addition, the company offers job work facility for manufacturing of pharmaceuticals drug. Biofil Chemicals and Pharmaceuticals Limited was founded in 1985 and is based in Indore, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Indore
- Employees
- 24
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Biofil Chemicals & Pharmaceuticals in the last day or two.
Dividends and corporate actions
All companies- Annual General Meeting
Action · ex-date 23 September 2024
- Annual General Meeting
Action · ex-date 20 September 2023
- Annual General Meeting
Action · ex-date 21 September 2022
- Annual General Meeting
Action · ex-date 17 September 2021
- Annual General Meeting
Action · ex-date 21 September 2020
- Annual General Meeting
Action · ex-date 18 September 2019
- Annual General Meeting
Action · ex-date 18 September 2018
- Annual General Meeting
Action · ex-date 14 September 2017
Source: NSE. Latest first, 8 of 19.
Information only, not investment advice. Prices are delayed.